Loading...

BioPorto

DB:2P4
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2P4
DB
DKK663M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
2P4 Share Price and Events
7 Day Returns
-0.4%
DB:2P4
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
36.1%
DB:2P4
-5.6%
DE Biotechs
-4.5%
DE Market
2P4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioPorto (2P4) -0.4% -0.2% -0.6% 36.1% - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 2P4 outperformed the Biotechs industry which returned -5.6% over the past year.
  • 2P4 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
2P4
Industry
5yr Volatility vs Market

Value

 Is BioPorto undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioPorto. This is due to cash flow or dividend data being unavailable. The share price is €0.517.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioPorto's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioPorto's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2P4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in DKK DKK-0.24
CPSE:BIOPOR Share Price ** CPSE (2019-04-25) in DKK DKK4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioPorto.

DB:2P4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:BIOPOR Share Price ÷ EPS (both in DKK)

= 4 ÷ -0.24

-16.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioPorto is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BioPorto is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioPorto's expected growth come at a high price?
Raw Data
DB:2P4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
65.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioPorto, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioPorto's assets?
Raw Data
DB:2P4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in DKK DKK0.34
CPSE:BIOPOR Share Price * CPSE (2019-04-25) in DKK DKK4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:2P4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:BIOPOR Share Price ÷ Book Value per Share (both in DKK)

= 4 ÷ 0.34

11.79x

* Primary Listing of BioPorto.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioPorto is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioPorto's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioPorto has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioPorto expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioPorto expected to grow at an attractive rate?
  • BioPorto's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioPorto's earnings growth is expected to exceed the Germany market average.
  • BioPorto's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2P4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2P4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 65.9%
DB:2P4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 44.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2P4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2P4 Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 378 212 1
2022-12-31 244 108 1
2021-12-31 147 34 1
2020-12-31 59 -36 2
2019-12-31 39 -42 2
DB:2P4 Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2018-12-31 26 -38 -38
2018-09-30 24 -40 -38
2018-06-30 25 -38 -36
2018-03-31 24 -36 -35
2017-12-31 25 -29 -32
2017-09-30 25 -26 -29
2017-06-30 23 -25 -27
2017-03-31 21 -21 -26
2016-12-31 21 -20 -23
2016-09-30 20 -21 -21
2016-06-30 20 -20 -16
2016-03-31 21 -18 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioPorto's earnings are expected to grow significantly at over 20% yearly.
  • BioPorto's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2P4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from BioPorto Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2P4 Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.12 1.12 1.12 1.00
2022-12-31 0.59 0.59 0.59 1.00
2021-12-31 0.20 0.20 0.20 1.00
2020-12-31 -0.13 -0.13 -0.13 1.00
2019-12-31 -0.26 -0.26 -0.26 1.00
DB:2P4 Past Financials Data
Date (Data in DKK Millions) EPS *
2018-12-31 -0.24
2018-09-30 -0.24
2018-06-30 -0.24
2018-03-31 -0.24
2017-12-31 -0.22
2017-09-30 -0.21
2017-06-30 -0.20
2017-03-31 -0.20
2016-12-31 -0.17
2016-09-30 -0.16
2016-06-30 -0.12
2016-03-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioPorto will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioPorto's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioPorto has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioPorto performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioPorto's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioPorto does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioPorto's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioPorto's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioPorto's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioPorto Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2P4 Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 26.02 -38.05 40.94 18.68
2018-09-30 23.94 -37.58 36.62 22.01
2018-06-30 24.54 -35.82 33.51 25.20
2018-03-31 24.03 -34.92 33.30 23.76
2017-12-31 25.16 -32.24 32.81 21.93
2017-09-30 24.62 -29.25 57.43 24.95
2017-06-30 23.25 -26.83 49.20 18.28
2017-03-31 21.28 -26.26 40.38 13.81
2016-12-31 20.72 -22.80 31.07 9.67
2016-09-30 20.21 -20.68 18.30 9.94
2016-06-30 20.29 -15.73 18.30 9.94
2016-03-31 21.44 -11.84 18.30 9.94
2015-12-31 20.38 -10.73 18.30 9.94
2015-09-30 19.52 -11.08 19.84 8.62
2015-06-30 19.40 -11.84 19.84 8.62
2015-03-31 18.08 -13.29 19.84 8.62
2014-12-31 18.71 -12.93 19.84 8.62
2014-09-30 18.18 -15.44 18.63 10.21
2014-06-30 18.59 -19.37 18.63 10.21
2014-03-31 18.37 -19.85 18.63 10.21
2013-12-31 16.63 -21.87 18.63 10.21
2013-09-30 17.11 -20.35 15.01 9.91
2013-06-30 16.35 -17.14 15.01 9.91
2013-03-31 15.78 -16.13 15.01 9.91
2012-12-31 17.86 -14.70 15.01 9.91
2012-09-30 17.28 -15.67 15.25 8.13
2012-06-30 17.23 -15.88 15.25 8.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioPorto has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioPorto has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioPorto improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioPorto's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioPorto has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioPorto's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioPorto's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioPorto is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioPorto's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioPorto's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioPorto has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioPorto Company Filings, last reported 3 months ago.

DB:2P4 Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 56.20 0.00 46.71
2018-09-30 26.46 0.00 13.49
2018-06-30 37.09 0.00 22.53
2018-03-31 45.40 0.00 33.75
2017-12-31 56.07 0.04 47.08
2017-09-30 21.22 0.00 13.28
2017-06-30 29.46 0.03 20.13
2017-03-31 36.37 0.03 29.21
2016-12-31 44.29 0.06 35.64
2016-09-30 27.15 0.07 18.99
2016-06-30 33.42 0.08 24.06
2016-03-31 39.32 0.08 29.67
2015-12-31 44.49 0.09 34.87
2015-09-30 46.35 0.09 41.15
2015-06-30 20.16 0.10 17.97
2015-03-31 24.71 0.10 22.00
2014-12-31 28.69 0.11 25.45
2014-09-30 32.14 0.11 29.92
2014-06-30 34.61 0.11 32.16
2014-03-31 39.25 0.12 36.11
2013-12-31 41.61 0.12 42.80
2013-09-30 46.96 0.00 45.75
2013-06-30 -11.91 22.17 6.47
2013-03-31 -6.78 13.70 3.11
2012-12-31 -1.15 13.23 8.35
2012-09-30 -7.57 12.76 2.20
2012-06-30 -4.37 13.38 6.68
  • BioPorto has no debt.
  • BioPorto has no debt compared to 5 years ago when it was 0.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioPorto has sufficient cash runway for 1.2 years based on current free cash flow.
  • BioPorto has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 30.7% each year.
X
Financial health checks
We assess BioPorto's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioPorto has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioPorto's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioPorto dividends.
If you bought €2,000 of BioPorto shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioPorto's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioPorto's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2P4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2P4 Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioPorto has not reported any payouts.
  • Unable to verify if BioPorto's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioPorto's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioPorto has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioPorto's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioPorto afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioPorto has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioPorto's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Eriksen
COMPENSATION DKK3,582,000
AGE 58
TENURE AS CEO 5.8 years
CEO Bio

Mr. Peter Mørch Eriksen, BBA, has been a Director at Fluoguide A/s since 2019. He serves as Chief Executive Officer of BioPorto Diagnostics A/S. Mr. Eriksen has been the Chief Executive Officer of BioPorto A/S since July 18,2013. Mr. Eriksen served as an Administration Director of BioPorto A/S. Mr. Eriksen serves as the Chief Executive Officer of Sense A/S. He has more than 15 years of experience within medtech/life science in Denmark and abroad. He served as Vice President of Medtronic in both the USA and Denmark. He has extensive experience in creating growth, restructuring and funding in technology intensive and complex companies. He has an accounting background supplemented with courses in management. He has long experience in selling and developing medical devices for both small and large medtech companies. He is an executive leader with a record of business within the medical device industry. He served as the Chief Executive Officer of Pnn Medical A/S from 2008 to 2009 and Vice President/General Manager of Medtronic Inc. from 1997 to 2004 in the US. He served as the Chief Operating Officer of Maconomy. He served as the Chief Executive Officer/Chief Financial Officer of Brüel & Kjaer. He contributes with to NORMA’s success with his executive skills in establishing international business organizations and strong understanding of the complexities of medical devices and their clinical trials. He serves as the Chairman of MTIC. He serves as a Member of Lund University Advisory Board and Director of PMEconsult. He serves as a Member of the Board at NORMA A/S.

CEO Compensation
  • Peter's compensation has been consistent with company performance over the past year.
  • Peter's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioPorto management team in years:

2.6
Average Tenure
57
Average Age
  • The tenure for the BioPorto management team is about average.
Management Team

Peter Eriksen

TITLE
Chief Executive Officer
COMPENSATION
DKK4M
AGE
58
TENURE
5.8 yrs

Ole Larsen

TITLE
Chief Financial Officer
COMPENSATION
DKK2M
AGE
53
TENURE
0.8 yrs

Jan Andersen

TITLE
Chief Operation Officer
COMPENSATION
DKK2M
AGE
57
TENURE
2.6 yrs

Lars Uttenthal

TITLE
Chief Scientific Officer

Gry Larsen

TITLE
General Counsel
Board of Directors Tenure

Average tenure and age of the BioPorto board of directors in years:

5.3
Average Tenure
62
Average Age
  • The tenure for the BioPorto board of directors is about average.
Board of Directors

Thomas Magnussen

TITLE
Chairman of the Board
COMPENSATION
DKK500K
AGE
65
TENURE
6.3 yrs

Torben Nielsen

TITLE
Vice Chairman
COMPENSATION
DKK350K
AGE
58

Jean-Louis Vincent

TITLE
Chairman of the Scientific Advisory Board

Andrew Lewington

TITLE
Vice Chairman of Scientific Advisory Board

Claudio Ronco

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Laurent Jacob

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Michael Haase

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Hilde Geus

TITLE
Member of Scientific Advisory Board
TENURE
5.3 yrs

Kirsten Drejer

TITLE
Director
COMPENSATION
DKK300K
AGE
62
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess BioPorto's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioPorto has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric test that measures NGAL that is used on clinical chemical analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for human use, as well as used in research and clinical practice; and MBL ELISA kit, which is based on MBL antibodies. It also provides monoclonal antibodies that cover various research disciplines, such as microbiology, immune deficiency, renal, peptide hormones, and plasma proteins. In addition, the company offers antigens, such as human monoclonal IgE. Further, it provides lateral flow platform gRAD for the development of assays. The company sells its products through own sales team, distributors, and OEM partnerships. BioPorto A/S was founded in 2000 and is headquartered in Hellerup, Denmark.

Details
Name: BioPorto A/S
2P4
Exchange: DB
Founded: 2000
DKK88,757,181
165,674,798
Website: http://www.bioporto.com
Address: BioPorto A/S
Tuborg Havnevej 15,
Ground floor,
Hellerup,
2900,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE BIOPOR Class B Common Stock OMX Nordic Exchange Copenhagen DK DKK 02. Jan 1992
DB 2P4 Class B Common Stock Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0JJM Class B Common Stock London Stock Exchange GB DKK 02. Jan 1992
BATS-CHIXE BIOPOC Class B Common Stock BATS 'Chi-X Europe' GB DKK 02. Jan 1992
Number of employees
Current staff
Staff numbers
28
BioPorto employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:19
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/02/27
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.